Global Polio Eradication – Way Ahead

In 1988, the World Health Assembly resolved to eradicate poliomyelitis by the year 2000. Although substantial progress was achieved by 2000, global polio eradication proved elusive. In India, the goal was accomplished in 2011, and the entire South-East Asia Region was certified as polio-free in 2014. The year 2016 marks the lowest wild poliovirus type 1 case count ever, the lowest number of polio-endemic countries (Afghanistan, Nigeria and Pakistan), the maintenance of wild poliovirus type 2 eradication, and the continued absence of wild poliovirus type 3 detection since 2012. The year also marks the Global Polio Eradication Initiative (GPEI) moving into the post-cessation of Sabin type 2, after the effort of globally synchronized withdrawal of Sabin type 2 poliovirus in April 2016. Sustained efforts will be needed to ensure polio eradication is accomplished, to overcome the access and security issues, and continue to improve the quality and reach of field operations. After that, surveillance (the “eyes and ears”) will move further to the center stage. Sensitive surveillance will monitor the withdrawal of all Sabin polioviruses, and with facility containment, constitute the cornerstones for eventual global certification of wild poliovirus eradication. An emergency response capacity is essential to institute timely control measures should polio still re-emerge. Simultaneously, the public health community needs to determine whether and how to apply the polio-funded infrastructure to other priorities (after the GPEI funding has stopped). Eradication is the primary goal, but securing eradication will require continued efforts, dedicated resources, and a firm commitment by the global public health community.

[1]  N. Turner Meeting of the Strategic Advisory Group of Experts on immunization, October 2016 – conclusions and recommendations. , 2016, Releve epidemiologique hebdomadaire.

[2]  R. Sutter,et al.  Completing Polio Eradication: The Case for Antiviral Drugs. , 2016, The Journal of infectious diseases.

[3]  M. Pallansch,et al.  Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient , 1998, Journal of Clinical Microbiology.

[4]  M. Vilayleck The WHO European Region declared free of polio. , 2002, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  Hong‐Mei Liu,et al.  Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model , 2016, The Journal of infectious diseases.

[6]  Certification of poliomyelitis eradication--Western Pacific Region, October 2000. , 2001, MMWR. Morbidity and mortality weekly report.

[7]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[8]  Javier Martin,et al.  Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative , 2015, PLoS pathogens.

[9]  L. Hampton,et al.  Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[10]  M. Wenner,et al.  Conclusions and recommendations , 2010, Annals of the New York Academy of Sciences.

[11]  W. Dowdle,et al.  The Biologic Principles of Poliovirus Eradication , 1997, The Journal of infectious diseases.

[12]  S. Cochi,et al.  Polio-Free Certification and Lessons Learned — South-East Asia Region, March 2014 , 2014, MMWR. Morbidity and mortality weekly report.

[13]  R. Sutter,et al.  49 – Poliovirus Vaccine–Live , 2018 .

[14]  R. Sutter,et al.  Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization , 2017, The Journal of infectious diseases.

[15]  Global eradication of poliomyelitis by the year 2000. , 1988, Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada.

[16]  M. Holubar,et al.  Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. , 2015, Vaccine.

[17]  M. Pallansch,et al.  Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. , 2014, The Journal of infectious diseases.

[18]  R. Sutter,et al.  Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.

[19]  Continued endemic wild poliovirus transmission in security-compromised areas – Nigeria, 2016. , 2017, Releve epidemiologique hebdomadaire.

[20]  W. Orenstein,et al.  Polio endgame: the global switch from tOPV to bOPV , 2016, Expert review of vaccines.

[21]  O. Kew Reaching the last one per cent: progress and challenges in global polio eradication. , 2012, Current opinion in virology.

[22]  Steven G F Wassilak,et al.  Progress Toward Polio Eradication - Worldwide, 2015-2016. , 2016 .

[23]  D. Rowlands,et al.  Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection , 2016, Journal of Virology.

[24]  F. Robbins,et al.  Certification of the eradication of indigenous transmission of wild poliovirus in the Americas. , 1997, The Journal of infectious diseases.

[25]  M. Pallansch,et al.  Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule. , 2017, Vaccine.

[26]  D A Henderson,et al.  Diagnosis and management of smallpox. , 2002, The New England journal of medicine.

[27]  M. Pallansch,et al.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.